Recent advances along clinical and neuropathological lines, as well as in our ability to detect the deposition of β-amyloid (Aβ) in vivo using positron emission tomography (PET), have helped redefine Alzheimer's disease (AD) as a dynamic clinicobiological entity. On the basis of these advances, AD is now conceptualized as a continuum comprising asymptomatic, minimally symptomatic, and dementia phases, with detection of brain Aβ -in particular, via PET amyloid imaging -central to the diagnostic process. In this respect, [ suggest that Aβ production, oligomerization and aggregation begins many years, possibly decades, before detectable cognitive impairment, with Aβ shown to associate with cognitive decline and conversion to dementia. While personalized medicine has now emerged as a prospect for the field, the recent decision by the Centers for Medicare & Medicaid Services (CMS) -who declined to cover the cost of amyloid PET imaging citing insufficient evidence to support its clinical utility -highlights that such a move may be premature.
Introduction
Historically, Alzheimer's disease (AD) has been conceptualized as a dual clinicopathological entity, comprising a progressive dementia syndrome -an amnestic core, followed by involvement of additional cognitive domains -and specific histologic features, including β-amyloid (Aβ) deposition. This framework assumed a static relationship between 
Revised conceptualization of AD: the IWG and NIA-AA diagnostic criteria
Though useful and widely adopted, the NINCDS-ADRDA criteria possessed several shortcomings, including insu cient diagnostic specificity [7, 8] and the fact that they only allowed for the diagnosis of AD to be made late in the disease course, once the threshold for dementia had already been reached. 13] findings have been conflicting [14, 15] with recent work failing to support this association [16] . Although significant advances have been made in CSF amyloid biomarkers, several methodological constraints limit their application in clinical practice, including high inter-laboratory variation, which hinders comparison of data obtained in different settings [17] . By contrast, amyloid PET imaging is associated with superior test-retest reliability and between-center comparability of cut-offs and interpretation [18, 19] .
Imaging Aβ deposition in AD using PET [ Aβ-containing lesions, including diffuse plaques, cerebrovascular amyloid [22] and Aβ-oligomers [23] . Showing robust retention in AD brain, [
11 C]PIB is the most widely studied amyloid tracer to date [24, 25] . High [ 11 C]PIB retention has also been observed in patients with MCI who later convert to AD [26, 27] and also in cognitively normal older individuals [28] [29] [30] . In addition to accelerating current understanding of cerebral amyloidosis and advancing detection of AD pathology to an earlier stage [20, 25, 31, 32] , [ F]florbetapir cortical to cerebellar (vermis excluded) standardized uptake value ratio (SUVR) -is seen in cortical regions expected to be high in amyloid deposition, such as the frontal cortex, temporal cortex and precuneus. In contrast, cognitively normal (CN) subjects exhibit tracer retention predominantly in white matter areas. T1-weighted MRI coronal images show hippocampal atrophy in both MCI (orange dashed circles) and AD (red dashed circles), as compared to controls (green dashed circles). medicine') [45] , one that applies technologies to achieve customized care delivery [46] . of data with which to evaluate its clinical utility [60] . Indeed, to date the majority of studies have -including the ability to make plans for the future -has not been addressed [61] . Finally, generalization from diagnostic performance studies is difficult given that study physicians were highly trained, with non-representative study populations due to enrichment with subjects characterized by high likelihood of AD [61] . 
Conclusion

